Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review

Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review

IntroductionChronic kidney disease (CKD) is a major public-health problem that increases the risk of end-stage kidney disease (ESKD), cardiovascular diseases, and other complications. Kidney transplantation is a renal-replacement therapy that offers better survival compared to dialysis. Antibody-med...

Full description

Bibliographic Details
Main Authors:	Lara Cabezas, Thomas Jouve, Paolo Malvezzi, Benedicte Janbon, Diane Giovannini, Lionel Rostaing, Johan Noble
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-04-01
Series:	Frontiers in Immunology
Subjects:	kidney transplantation tocilizumab antibody-mediated rejection chronic active antibody-mediated rejection estimated glomerular filtration rate donor-specific alloantibody
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.839380/full

Similar Items

Tocilizumab in the Treatment of Chronic Antibody-Mediated Rejection Post Kidney Transplantation: Clinical and Histological Monitoring
by: Johan Noble, et al.
Published: (2021-12-01)

Early Exposure of Kidney Transplant Recipients with Chronic Antibody-Mediated Rejection to Tocilizumab—A Preliminary Study
by: Capucine Arrivé, et al.
Published: (2023-11-01)

Tocilizumab and Desensitization in Kidney Transplant Candidates: Personal Experience and Literature Review
by: Jules Weinhard, et al.
Published: (2021-09-01)

Tocilizumab Evaluation in HLA-Desensitization before Kidney Transplantation as an Add-On Therapy to Apheresis: The TETRA Study
by: Thomas Jouve, et al.
Published: (2023-01-01)

Efficacy and safety of bortezomib in the treatment of active antibody-mediated rejection in adult kidney-transplant recipients: A single-center retrospective study
by: Dharmendra Bhadauria, et al.
Published: (2022-01-01)

Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study)
by: Lillian Streichart, et al.
Published: (2024-03-01)

Tocilizumab en el tratamiento del rechazo humoral crónico activo resistente a terapia estándar
by: Betty Chamoun, et al.
Published: (2022-09-01)

Tocilizumab Trough Levels Variability in Kidney-Transplant Candidates Undergoing Desensitization
by: Aurélie Truffot, et al.
Published: (2021-12-01)

Treatment of Antibody-Mediated Rejection in Kidney Transplantation
by: Magdalena Durlik
Published: (2013-07-01)

Spot Urine Protein Excretion in the First Year Following Kidney Transplantation Associates With Allograft Rejection Phenotype at 1-Year Surveillance Biopsies: An Observational National-Cohort Study
by: Manca Oblak, et al.
Published: (2021-11-01)

Pre-existing Alloreactive T and B Cells and Their Possible Relevance for Pre-transplant Risk Estimation in Kidney Transplant Recipients
by: Gonca E. Karahan, et al.
Published: (2020-07-01)

Rigetto anticorpo-mediato nel trapianto di rene: fisiopatologia, clinica e terapia
by: Aris Tsalouchos, et al.
Published: (2020-10-01)

Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial
by: Katharina A. Mayer, et al.
Published: (2022-04-01)

Pathophysiology of Rejection in Kidney Transplantation
by: Christina L. Tamargo, et al.
Published: (2023-06-01)

Artemisinin Attenuates Transplant Rejection by Inhibiting Multiple Lymphocytes and Prolongs Cardiac Allograft Survival
by: Zhe Yang, et al.
Published: (2021-02-01)

Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation
by: Farah Abuazzam, et al.
Published: (2023-07-01)

Clinical significance of donor-specific anti-HLA-DR51/52/53 antibodies for antibody-mediated rejection in kidney transplant recipients
by: Borae Geum Park, et al.
Published: (2019-09-01)

Allograft rejection in kidney transplantation – A retrospective study of impact on graft and patient outcome
by: M P Shamsudheen, et al.
Published: (2022-01-01)

Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design
by: Peter W. Nickerson, et al.
Published: (2022-12-01)

Antibody-mediated rejection in heart transplantation
by: V. S. Kvan, et al.
Published: (2022-01-01)

Characteristics of Donor-Specific Antibodies Associated With Antibody-Mediated Rejection in Lung Transplantation
by: Antoine Roux, et al.
Published: (2017-10-01)

Perturbations of the T-cell immune repertoire in kidney transplant rejection
by: Tara K. Sigdel, et al.
Published: (2022-11-01)

Clinical and Analytical Validation of a Novel Urine-Based Test for the Detection of Allograft Rejection in Renal Transplant Patients
by: Niamh Nolan, et al.
Published: (2020-07-01)

The Role of the Endothelium during Antibody-Mediated Rejection: From Victim to Accomplice
by: Amy Rachael Cross, et al.
Published: (2018-01-01)

Specialized Roles of Human Natural Killer Cell Subsets in Kidney Transplant Rejection
by: Katrina Kildey, et al.
Published: (2019-08-01)

The New Challenge in Pediatric Liver Transplantation: Chronic Antibody-Mediated Rejection
by: Elena Yukie Uebayashi, et al.
Published: (2022-08-01)

Treatment of donor‐specific antibody‐mediated rejection after heart transplantation by IgM‐enriched human immunoglobulin
by: Moritz Benjamin Immohr, et al.
Published: (2021-08-01)

Vascular rejection in cardiac allograft vasculopathy: Impact on graft survival
by: Nandini Nair
Published: (2022-08-01)

Mouse Model Established by Early Renal Transplantation After Skin Allograft Sensitization Mimics Clinical Antibody-Mediated Rejection
by: Daqiang Zhao, et al.
Published: (2018-07-01)

A modified perioperative regimen for deceased donor kidney transplantation in presensitized recipients without prior desensitization therapy
by: Zhiliang Guo, et al.
Published: (2023-07-01)

Editorial: T-Cell and Antibody-Mediated Rejection After Organ Transplantation in the Post-COVID-19 Era – Diagnosis, Immunological Risk Evaluation and Therapy
by: Antonij Slavcev, et al.
Published: (2022-07-01)

ACCELERATED HUMORAL (ANTIBODY-MEDIATED) REJECTION OF THE CARDIAC ALLOGRAFT (A CASE REPORT)
by: A. G. Kupriyanova, et al.
Published: (2011-06-01)

DISTURBANCE OF THE CARDIOMYOCYTE’S MACROMOLECULAR STRUCTURE IN HEART ALLOGRAFTS AS A SIGN OF CHRONIC REJECTION
by: A. G. Kupriyanova, et al.
Published: (2012-12-01)

Impact of Preformed Donor-Specific Anti-HLA-Cw and Anti-HLA-DP Antibodies on Acute Antibody-Mediated Rejection in Kidney Transplantation
by: Timothée Laboux, et al.
Published: (2023-11-01)

Challenges of Diagnosing Antibody-Mediated Rejection: The Role of Invasive and Non-Invasive Biomarkers
by: Sambhavi Krishnamoorthy, et al.
Published: (2021-05-01)

Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial
by: Farsad Eskandary, et al.
Published: (2019-01-01)

Difficult-to-Treat Rejections in Kidney Transplant Recipients: Our Experience with Everolimus-Based Quadruple Maintenance Therapy
by: Pierre Larsson, et al.
Published: (2023-10-01)

Peripheral Blood RNA Sequencing Unravels a Differential Signature of Coding and Noncoding Genes by Types of Kidney Allograft Rejection
by: Silvia Pineda, et al.
Published: (2020-10-01)

Misidentification of preformed anti-HLA-DP antibodies leads to antibody-mediated kidney transplant rejection: a case report
by: Duangtawan Thammanichanond, et al.
Published: (2022-05-01)

Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation
by: Yunhui Li, et al.
Published: (2023-10-01)